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Abstract Phosphatidylinositol transfer proteins (PITPs)
bind phosphatidylinositol (PtdIns) and phosphatidylcholine
and play diverse roles in coordinating lipid metabolism/
signaling with intracellular functions. The underlying mech-
anisms remain unclear. Genetic ablation of PITPa in mice
results in neonatal lethality characterized by intestinal and
hepatic steatosis, spinocerebellar neurodegeneration, and
glucose homeostatic defects. We report that mice express-
ing a PITPa selectively ablated for PtdIns binding activity
(PitpaT59D), as the sole source of PITPa, exhibit pheno-
types that recapitulate those of authentic PITPa nullizygotes.
Analyses of mice with graded reductions in PITPa activity
reveal proportionately graded reductions in lifespan, dem-
onstrate that intestinal steatosis and hypoglycemia are ap-
parent only when PITPa protein levels are strongly reduced
(>90%), and correlate steatotic and glucose homeostatic
defects with cerebellar inflammatory disease. Finally, recon-
stitution of PITPa expression in the small intestine sub-
stantially corrects the chylomicron retention disease and
cerebellar inflammation of Pitpa0/0 neonates, but does not
rescue neonatal lethality in these animals. These data
demonstrate that PtdIns binding is an essential functional
property of PITPa in vivo, and suggest a causal linkage be-
tween defects in lipid transport and glucose homeostasis and
cerebellar inflammatory disease. Finally, the data also dem-
onstrate intrinsic neuronal deficits in PITPa-deficient mice
that are independent of intestinal lipid transport defects and
hypoglycemia.—Alb, J. G., Jr., S. E. Phillips, L. R. Wilfley,
B. D. Philpot, and V. A. Bankaitis.The pathologies associated
with functional titration of phosphatidylinositol transfer pro-
tein a activity in mice. J. Lipid Res. 2007. 48: 1857–1872.
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The physical compartmentation of signal transduction
to specific microdomains of membrane surfaces is a com-
mon property of all eukaryotic cells, and various mech-
anisms are applied toward achieving this end (1–5). One
such mechanism involves the spatially and temporally
regulated metabolic channeling of phosphatidylinositol
(PtdIns) and/or phosphatidylcholine (PtdCho) monomers
by phosphatidylinositol transfer proteins (PITPs). This
PITP-mediated channeling is itself linked to specific physi-
ological outcomes (6–8). Prime among these are the roles
of PITPs in coordinating various interfaces between lipid
metabolism and membrane trafficking reactions. PITPs
fall into two unrelated structural classes: the Sec14-like
PITPs and the so-called class 1 metazoan PITPs (9–12). The
Sec14-like PITPs are better understood because detailed
functional analyses have been more accessible for these pro-
teins. The metazoan PITPs are poorly characterized from
a functional point of view.
Mammals express four known class 1 PITP forms: PITPa,
PITPb, an alternative spliceoform of PITPb, and rdgBb
(13–18). Data that address in vivo functions for PITPa
and PITPb are building. These proteins are encoded by
distinct genes but are highly similar, sharing 77% and
95% primary sequence identity and similarity, respectively.
The extensive homology notwithstanding, available data
suggest that PITPa and PITPb execute distinct roles in
mammals. First, these proteins exhibit distinct intracel-
lular distributions. PITPa represents a cytosolic/nuclear
protein, whereas PITPb is localized predominantly to the
trans-Golgi network of mammalian cells [as is its alterna-
tive spliceoform (17)]. Second, PITPb binds the ceramide-
based phospholipid sphingomyelin, whereas PITPa does
not (15, 17, 19). Finally, the consequences of the genetic
ablation of each protein are different (20, 21). The func-
tional nonredundancy of PITPa and PITPb conforms to
the general theme that PITPs are tightly coupled to spe-
cific physiological functions in cells (6–8). How PITPs couple
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individual PtdIns and PtdCho binding activities to bio-
logical functions remains to be determined.
Genetic ablation of the PITPa structural gene in mice
has interesting consequences. Pitpa0/0 progeny develop to
term, but expire within several days after birth from a com-
plex disease course that includes defects in dietary fat and
a-tocopherol transport from the small intestine [chylo-
micron retention disease (CRD)], liver steatosis, hypogly-
cemia, inflammation of cerebellum and hindbrain, and
spinocerebellar neurodegenerative disease (21). These pa-
thologies raise a number of questions. First, which bio-
chemical properties of PITPa are relevant for in vivo
function (i.e., are the PtdIns and PtdCho binding activ-
ities differentially used in vivo, or are these themselves
coupled?). Second, which of these pathologies are caus-
ally linked, and which derive from independent insults?
It is suggested the intestinal defects and hypoglycemia
are linked, and that these defects provoke the cerebellar
and hindbrain neurodegenerative diseases (21). Resolu-
tion of these questions is key to an understanding of
PITPa function in mammalian systems.
Here, we show that PtdIns binding is an essential func-
tional property of PITPa in mammals. It is further
demonstrated that intestinal steatosis and hypoglycemia
require manifest reductions in PITPa activity, and that these
pathologies correlate with cerebellar inflammatory disease.
Finally, the data indicate that reconstitution of PITPa ex-
pression in the small intestine alleviates the CRD and cer-
ebellar inflammatory disease of Pitpa0/0 neonates, but fails to
effectively rescue the neonatal lethality of these animals. This
failure is accompanied by exacerbations in microvesicular
steatosis of the liver, a result consistent with the idea that
PITPa regulates the trafficking of luminal lipid cargos.
MATERIALS AND METHODS
Mouse genotyping
Wild-type and Pitpa::NEO alleles were diagnosed from tail clip
genomic DNA templates using a three-primer PCR assay de-
scribed previously (21). To screen for the vibrator allele (Pitpavb),
a hypomorphic mutation that reduces the expression of wild-
type PITPa by ?80%, an intracisternal A particle retrotransposon
three-primer PCR assay was used (22). The allele-specific for-
ward primers for the wild-type and vibrator alleles were Ham-
For (5¶-AGTGATCGGGACTTTTGTTTCC-3¶) and intracisternal A
particle retrotransposon-1 (5¶-AACGCGTCTAATAACACTTGTG-
3¶), respectively. A common reverse primer was used, Ham-Rev
(5¶-CCAAAAGGACTGCCCAGTCATTTTTCCCC-3¶). The vibrator
primer sequences were provided courtesy of Bruce Hamilton
(University of California at San Diego).
To generate a PITPa transgene whose expression is limited
to the duodenum, plasmid pNSE-EX4 (23) (a gift of Greg Cox,
Jackson Laboratories, Bar Harbor, ME) was cleaved with XhoI to
remove the existing neuronal enolase promoter, and the intes-
tinal fatty acid binding promoter (PIFABP) (24) was introduced
in its stead. The PITPa open reading frame cDNA was generated
by PCR as a 5¶-Hind III-EcoRI-3¶ fragment and correspondingly
subcloned into the PIFABP-pNSE-EX4 vector to yield plasmid
pFabpiPITPa. The resultant plasmid was linearized by digestion
with restriction endonuclease Sal I and injected into C57BL/
6J3C3H hybrid pronuclei at the University of North Carolina
Animals Model Core to generate transgenic murine founder lines.
Transgenic founders were identified with a PITPa cDNA-specific
set of primers: Alpha-For (5¶-GCAAAGTTCCCACGTTTGTTCG-
3¶) and Alpha-Rev (5¶-CTCTTGCTTATGTATAAAGTTTTCC-3¶).
These primers support the synthesis of a diagnostic 450 bp PCR
product. Three independent founders were crossed to C57BL/6J
PITPa1/0 mice to generate Pitpa1/0;Tg(PIFABP::PITPa) lines.
Generation of a PtdIns binding-deficient PITPa transgene
Escherichia coli strain DY380 was transformed with P1 clone
4232 (a gift from Bruce Hamilton, University of California at
San Diego), which contains the entire PITPa genomic locus in a
P1 artificial chromosome (PAC) vector harboring a kanamycin
resistance selection marker, to generate E. coli strain DY380-
Tg(PITPa). DY380 is permissive for homologous recombination
when electroporated linear double-stranded DNA is introduced
into this E. coli host (25, 26). The T59D missense substitution was
incorporated into exon 3 of the PITPa gene as follows. A pair of
100mer oligonucleotides precisely complementary to each other
in their respective 3¶ 20 nucleotides was constructed. The 20 bp
complementary regions spanned the threonine 59 codon, which
was converted during oligonucleotide synthesis from the wild-
type ACA nucleotide sequence to GAG (and the corresponding
reverse complement). Oligonucleotides were annealed at 42jC
for 1 h, and the remaining 3¶ recessed ends were filled in with
Klenow fragment of DNA polymerase I (Promega, Madison, WI).
The resultant 200 bp linear double-stranded DNA fragment
represented the targeting cassette for incorporating the T59D
missense mutation into exon 3 of the PITPa structural gene.
The 200 bp target fragment was electroporated into DY380-
Tg(PITPa) cells prechallenged at 42jC for 15 min (to induce
the recombineering machinery), transformants were selected in
Luria broth supplemented with kanamycin (50 mg/ml), survivors
were serially diluted into five 96-well culture plates to a density
of ?10 colony-forming units per well, and the individual pools
were expanded. Aliquots from each well were collected and cor-
responding DNA templates were prepared for screening using
a mismatch amplification mutation assay (MAMA) PCR. MAMA-
PCR used a forward primer (5¶-GGCGAGAAAGGCGAGTACGAG-
3¶) specific for the mutant T59D codon (underlined) and reverse
primer (5¶-CTCACATGCCACACACTCC-3¶) that hybridizes to se-
quences within the PITPa gene not represented in the original
200 bp targeting fragment. Aliquots yielding a 300 bp PCR product
diagnostic of PitpaT59D clones identified the wells of interest, and
the corresponding well cultures were subjected to limit dilution
and plated for single colonies. Individual colonies derived from
well pools of interest were rescreened by MAMA-PCR. Positive
clones yielded candidate purified P1 Tg(PitpaT59D clones. Identities
were verified by nucleotide sequence analysis of PITPa exon 3 of
individual candidates. We estimate a 1:12,000 ratio of Tg(PitpaT59D)
to Tg(PITP a) in the final pools.
Immunoblotting and ELISA
Whole mouse brains or duodenal sections were solubilized in
RIPA buffer (50 mM Tris-HCl, pH 7.2, 1.0% Nonidet P-40, 0.1%
SDS, 0.15 mM NaCl, and 13 protease inhibitor cocktail tablet;
Roche, Indianapolis, IN). Protein was estimated using BCA (Pierce,
Rockford, IL) for purposes of normalization in immunoblot and
ELISA experiments. For immunoblotting experiments, 75 mg of
brain lysate was resolved by SDS-PAGE and transferred to nitro-
cellulose membrane (Bio-Rad Laboratories, Hercules, CA). Mem-
branes were subsequently decorated with PITPa-specific antibody
as described previously (20), and with a b-actin specific antibody
(Oncogene, Carpinteria, CA) for purposes of normalization. For
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ELISA analyses, serial amounts of brain lysate protein for each
experimental sample (1 mg, 100 ng, and 10 ng) were coated, in
duplicate, on 96-well plastic plates. Samples were dried overnight,
washed in 0.5% Tween 20, blocked with 2% BSA, incubated
with the appropriate primary antibody overnight at room tem-
perature, washed in PBS, incubated with secondary antibody, and
finally developed using o-phenylenediamine reagent (Sigma, St.
Louis, MO).
Blood chemistry
Whole blood was collected from mice immediately after de-
capitation or via heart puncture (in 2 mM EDTA, pH 7.2, final
concentration for plasma), clotted, and clarified by low-speed
centrifugation. Serum glucose was determined by the Trinder
assay (Sigma). Plasma triglyceride (TG) measurements were per-
formed on 30 ml plasma aliquots at the Animal Clinical Chem-
istry and Gene Expression Laboratories at the University of
North Carolina-Chapel Hill. Agarose electrophoresis of whole
serum used the Titan Gel Lipoprotein Kit (Helena Laboratories,
Beaumont, TX) according to the manufacturer’s specifications.
Resolved samples were developed by staining of gels in 0.1%
Fat Red 7B (w/v) in 95% methanol. Chylomicron densities
were determined by scanning dried Titan gels using a Bio-Rad
VersaDoc imaging system (525 nm) and quantified by the Quan-
tity One software package.
Whole carcass analyses
Carcass compositional analyses were performed as described
(21). Briefly, eviscerated carcasses were weighed and body water
content determined after drying. Dried carcasses were ground to
homogeneity and extracted with petroleum ether in a Soxhlet
apparatus to determine fat mass and fat-free dry mass. Carcass ash
was measured after limit incineration of fat-free dry mass material.
Histological methods
Mice were prepared for all analyses by anesthesia with 1.25%
Avertin (Sigma) and fixed by heart perfusion with sequential
phosphate-buffered saline and 4% paraformaldehyde solutions.
Intestines, brains, and livers were harvested, intestines were flushed
with fixative, and all tissues were postfixed in 4% paraformaldehyde
for 24 h. When dehydration was required, tissues were embedded
in paraffin, and 5 mm thick sections were cut and mounted onto
slides. When frozen samples were required, tissues were embedded
in OCT, and 12 mm thick sections were cut and mounted.
For intestinal and liver staining with osmium (27), paraffin
sections were rehydrated in a step series starting with xylene
and terminating with 50% ethanol (EtOH) (i.e., xylene, 95%
EtOH, 90% EtOH, 80% EtOH, 70% EtOH, 60% EtOH, and
50% EtOH), stained for total lipid by incubation with 5% potas-
sium dichromate and 2% OsO4 for 8 h, and counterstained
with toluidine blue O. Samples were then dehydrated in a 50%
EtOH-to-xylene series that was the reverse of the rehydration
series described above. Dehydrated sections were mounted in
Permount (Fisher Scientific, Atlanta, GA). Oil Red O staining was
used to identify neutral lipid (27). Frozen sections mounted onto
slides were incubated in 85% propylene glycol, stained with Oil Red
O, counterstained with hematoxylin, and mounted in glycerol.
For whole brain analyses, fixed samples were washed for sev-
eral days in phosphate-buffered saline. Brains were then sliced
in half along the sagittal plane and embedded in paraffin, and
5 mm-thick sections were cut. Sections were rehydrated as de-
scribed above and incubated with anti-glial fibrillary acidic pro-
tein (GFAP) antibody (EMD Biosciences CalBiochem, San Diego,
CA). Decorated slices were developed with the Vectastain ABC
kit (Vector Laboratories, Burlingame, CA), followed by counter-
staining with toluidine blue. Samples were finally dehydrated in
xylene/EtOH (50%) and mounted in Permount (Fisher Scientific).
a-Tocopherol measurements
Whole brains were harvested from decapitated mice, and a-
tocopherol was extracted with chloroform as described (21). Sam-
ples were resolved by HPLC using a Perkin-Elmer Life Sciences
model LC200 gradient pump with an AS 200 Autosampler and
an LC 295 ultraviolet-visible light detector.
Liver glycogen analysis
Whole livers were extracted from euthanized animals and
homogenized, and glycogen was recovered by acid extraction
(28). Recovered material was quantitatively hydrolyzed to glu-
cose by amyloglucosidase, and released glucose was quantified by
Trinder assay (Sigma).
Hippocampal field excitatory postsynaptic
potential recordings
Age-matched (P4–P6) PITPa1/1 and Pitpa0/0 mice were anes-
thetized with an overdose of pentobarbital barbiturate and
decapitated upon the disappearance of corneal reflexes, in com-
pliance with U. S. Department of Health and Human Services
and University of North Carolina guidelines. Brains were dis-
sected immediately, and dorsal hippocampi were cut in 400 mm
coronal slices in ice-cold oxygenated dissection buffer (75 mM
sucrose, 87 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 26 mM
NaHCO3, 10 mM glucose, 7 mM MgCl2, 0.5 mM CaCl2, and
1.3 mM ascorbic acid). Hippocampal slices were equilibrated for
30 min in a submersion chamber at 35jC filled with artificial
cerebrospinal fluid (124 mM NaCl, 3 mM KCl, 1.25 mM Na2PO4,
26 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, and 20 mM D-
glucose, saturated with 95% O2 and 5% CO2; ?315 mOsm and
pH ? 7.25) and then held at room temperature until use. For
recordings, hippocampal slices were placed in an interface cham-
ber, maintained at 31jC, and perfused with oxygenated artificial
cerebrospinal fluid. Synaptic responses were evoked by stimu-
lating the Schaffer collaterals with a bipolar stimulating electrode
(FHC, Inc., Bowdoin, ME), and field excitatory postsynaptic po-
tentials (fEPSPs) were recorded in stratum radiatum of the CA1
region. Input-output curves were generated by systematically
varying the stimulation intensity and measuring the fEPSP slope.
Fiber volley amplitude was compared with the fEPSP slope to
relate presynaptic to postsynaptic responses. The paired-pulse
facilitation of the fEPSP slope and amplitude was examined by
adjusting the stimulation intensity to the half-maximal response
and systematically varying the interstimulus interval between
two stimulations. Statistical analyses used a multivariate two-way
ANOVA, with significance placed at P , 0.05.
RESULTS
A murine strain that exclusively expresses a PtdIns
binding-deficient PITPa
PITPa binds/exchanges PtdIns and PtdCho monomers
between membrane bilayers in vitro. It is not yet estab-
lished what each individual activity contributes to PITPa
action in cells. The availability of mutant PITPa deriva-
tives with selective defects in PtdIns binding (29), and the
ability to generate PITPa nullizygous (Pitpa0/0) mice with
outstanding phenotypes (21), permit experimental assay
of the contribution of PtdIns binding to PITPa function
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in the mammal. To this end, the mutant PitpaT59D was
used to assess the in vivo consequences of inactivating
PITPa PtdIns binding activity. Residue threonine 59 is
required for coordination of the inositol headgroup of
PtdIns, and the introduction of any residue bulkier than
threonine at this position evokes a selective steric incom-
patibility with PtdIns binding (Fig. 1) (10, 29, 30). Because
choline is less bulky than inositol, PtdCho binding is un-
affected in PitpaT59D.
The strategy used for generating mice that express
only PitpaT59D involved recombineering-mediated site-
directed mutagenesis of a 76 kDa PAC containing the en-
tire PITPa genomic locus. This PAC [henceforth referred
to as Tg(PITPa)] was shown previously to phenotypically
complement the hypomorphic PITPa vibrator mutation
(22). As a control for all subsequent experiments, we tested
whether Tg(PITPa) also rescues Pitpa0/0 lethality. Indeed,
Tg(PITPa) efficiently complements all Pitpa0/0-associated
phenotypes. Pitpa0/0;Tg(PITPa) animals are long-lived
(the oldest animals are 16 months of age at present and
healthy), are fertile, and are phenotypically PITPa1/1 in
all obvious respects (data not shown). Thus, the Tg(PITPa)
vector is a suitable precursor for the expression of mutant
forms of PITPa in the mouse for functional studies.
The PITPa PAC mutagenesis scheme is outlined in
Fig. 2A. The PitpaT59D PAC [referred to as Tg(PitpaT59D)]
was injected into C57BL/6J3C3H hybrid pronuclei to gen-
erate founder mice. Standard mating strategies were used to
generate PITPa1/0;Tg(PitpaT59D) parental lines from which
Pitpa0/0;Tg(PitpaT59D) progeny were derived. The presence
of Tg(PitpaT59D) was diagnosed by probing for DNA se-
quences unique to the bacterial plasmid backbone of this
vector (Fig. 2B) (see Materials and Methods). However,
because an intact 76 kDa PITPa locus was used as the muta-
genesis substrate, diagnostic assays for Tg(PitpaT59D) were
more complicated. Additional methods were required to
independently confirm mouse genotypes (see below). To
that end, a robust MAMA-PCR strategy that distinguishes
the endogenous PITPa locus from ectopic Tg(PitpaT59D)
was developed for purposes of diagnostic genotyping of
transgenic mice (see Materials and Methods) (Fig. 2B).
Demonstration that this assay reliably detects PitpaT59D in
genomic DNA preparations is shown in Fig. 2C.
That Tg(PitpaT59D) is transcribed was verified by two
lines of evidence. First, reverse transcription PCR using the
same primers used for MAMA-PCR detected Tg(PitpaT59D)
mRNA only in Tg(PitpaT59D) mice (Fig. 2D). Second, DNA
sequence analysis of the entire PITPa cDNA coding se-
quence generated by reverse transcription of brain mRNA
from PITPa1/0;Tg(PitpaT59D) animals identified a single
polymorphism. This polymorphism resulted in the detec-
tion of both threonine and aspartate codons at PITPa
codon 59 [from PITPa1 and PitpaT59D alleles, respectively
(Fig. 2E, left and middle panels)]. The similar magnitudes
with which each polymorphism was recorded indicate that
Tg(PitpaT59D) supports transcriptional expression at levels
comparable to those of endogenous PITPa.
PtdIns binding/transfer is required for PITPa function
in mammals
Standard matings between PITPa1/0;Tg(PitpaT59D) males
and females generated the full complement of expected
genotypes. As all PITPa-sufficient progeny exhibited phe-
notypes indistinguishable from the wild type, irrespective
of their Tg(PitpaT59D) genotype, we restricted our attention
to comparisons of PITPa1/1;Tg(PitpaT59D), Pitpa0/0, and
Pitpa0/0;Tg(PitpaT59D) littermates. Lifespan-monitoring ex-
periments demonstrated that Tg(PitpaT59D) expression does
not rescue the neonatal and perinatal lethality of other-
wise PITPa nullizygous offspring. For Pitpa0/0;Tg(PitpaT59D)
progeny, the rapid onset of postnatal mortality character-
istic of PITPa nullizygous mice was on display (Fig. 3A).
Comparison of Pitpa0/0 and Pitpa0/0;Tg(PitpaT59D) progeny
at P3 and P6 revealed that both strains exhibited the wast-
ing phenotype typical of PITPa nullizygotes. This wasting
was associated with dramatic reductions in the contribution
of subcutaneous fat to total body mass (data not shown).
Additional analyses of Pitpa0/0;Tg(PitpaT59D) mice demon-
strated that these also exhibited the striking hypoglycemia
and intestinal and liver microvesicular steatosis disorders
that accompany PITPa nullizygosity (Table 1). Phenotypic
manifestations of the robust neurodegenerative disease
characteristic of Pitpa0/0 neonates were also apparent (data
not shown). In sum, the Pitpa0/0 and Pitpa0/0;Tg(PitpaT59D)
phenotypes were indistinguishable based on criteria of
severity and rate of onset.
Failure of Tg(PitpaT59D) to rescue lethality, or the other
various pathologies of Pitpa0/0 mice, revealed an intrinsic
biological nonfunctionality of PitpaT59D. Lack of activity
was not a consequence of reduced protein expression or
stability. Immunoblotting for PITPa in total brain, duo-
denum, and liver extracts culled from appropriate mouse
strains showed that PitpaT59D levels are comparable to
those of PITPa in vivo (Fig. 3C). For final confirmation,
Fig. 1. Residue threonine 59 (T59) and phosphatidylinositol transfer
protein a (PITPa)-mediated phosphatidylinositol (PtdIns) binding/
exchange activity. Left panel: The van der Waals space of PITPa
residue threonine 59 is depicted in mesh mode (violet), whereas
the van der Waals space of the inositol ring of bound PtdIns is
rendered in dot mode (red and yellow). Note how closely the thre-
onine 59 side chain abuts inositol ring space. Right panel: Same as
the left panel except an aspartate side chain is modeled for thre-
onine at PITPa residue 59 to depict the T59D missense mutation.
The aspartate 59 van der Waals space is rendered in green mesh.
Note the steric incompatibility between aspartate 59 and the ino-
sitol ring of PITPa-bound PtdIns. Both PITPa and PitpaT59D images
were generated with PyMOL 0.99 using the PtdIns-bound PITPa
crystal structure as a framework (Protein Data Bank accession num-
ber 1UW5) (30).
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Fig. 2. Generation of mice expressing a PtdIns binding-deficient PITPa. A: P1 artificial chromosome (PAC)
mutagenesis strategy. Tg(PITPa1) represents P1 clone 4232, which contains the entire 76 kb PITPa1
structural gene. The PitpaT59D missense substitution was introduced into this PAC by recombineering-driven
site-directed mutagenesis, as described in Materials and Methods. dNTP, deoxynucleoside triphosphate. B:
Diagnosis of Tg(PitpaT59D) in mouse genomic DNA. The mutant transgene was detected in candidate
transgenic mouse founder lines using a PCR strategy screening for the presence of the PAC vector backbone.
Arrows indicate the positions of forward and reverse diagnostic PCR primers that yield a 350 bp product
detected exclusively in genomic DNA prepared from founder mice carrying Tg(PitpaT59D). C: Confirma-
tion of Tg(PitpaT59D) in candidate transgenic founder lines. Arrows indicate primers used in mismatch
amplification mutation assay (MAMA)-PCR analysis (which yields a 300 bp PCR product; left panel) to
specifically reveal the PitpaT59D allele. D: Tg(PitpaT59D) is actively transcribed. The upper panel illustrates the
RT-PCR strategy used to detect transcripts in Tg(PitpaT59D) mice. Solid arrows indicate MAMA-PCR primers
used to distinguish endogenous PITPa1 mRNA (WT59-5) transcripts from those of PitpaT59D (TD59-5). In
both cases, the diagnostic PCR products are 350 bp. Dashed arrows indicate the forward and reverse PCR
primers (PITP-5 and PITP-3) used in RT-PCR assays to reveal full-length PITPa transcripts (820 bp product)
without distinguishing PITPa1 transcripts from those of PitpaT59D. The lower panel demonstrates this
method. Mouse genotype is indicated at the top and RT-PCR products are identified at the bottom of
individual lanes. E: Confirmation that PitpaT59D is properly expressed. Nucleotide sequence analysis of the
RT-PCR product generated by the PITP-5/PITP-3 primer combination. The left panel shows the cDNA
sequence readout of relevant codons from a PITPa1/1 mouse. The middle and right panels are the
corresponding readouts from PITPa1/0,Tg(PitpaT59D) and Pitpa0/0,Tg(PitpaT59D) mice, respectively. Geno-
types are indicated at the top, and relevant sequences are identified at the top of the red boxes.
Corresponding amino acids are listed: Asp, aspartate; Thr, threonine. Note that the PITPa1/0,Tg(PitpaT59D)
reactions reveal sequences derived from both PITPa1 from PitpaT59D alleles.
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mRNA was purified from brains of Pitpa0/0;Tg(PitpaT59D)
progeny, and the total brain mRNA fraction was used to
template PITPa cDNA synthesis. The templating strategy
sustained unbiased synthesis of both PITPa1 and PitpaT59D
cDNAs. The open reading frame sequence of PITPa cDNA
was then determined. These analyses confirmed PitpaT59D
as the sole detectable PITPa species expressed in Pitpa0/0;
Tg(PitpaT59D) mice (Fig. 2E, right panel). We conclude from
these experiments that PtdIns binding is essential for
PITPa biological activity.
An allelic series for titrating PITPa expression in mice
PITPa-deficient mice elaborate multiple phenotypes.
Manifestation of some of these phenotypes is sensitive to
amounts of PITPa protein (21, 22). These findings sug-
gest that titration of PITPa function in mice is a viable
approach for discerning relationships between the com-
plex phenotypes that accompany PITPa insufficiencies.
To this end, we took advantage of the availability of Pitpa0
and Pitpavb alleles to create a series of murine strains with
graded levels of PITPa expression. The Pitpavb allele re-
duces the expression of wild-type PITPa as a result of the
insertion of an IAP element into intronic sequences of
the PITPa structural gene (22). Because the Pitpa0 allele
was originally fixed in the 129SVJ genetic background, and
the hypomorphic Pitpavb phenotype is sensitive to genetic
modifiers (22), Pitpa0 was incorporated into the C57BL/6J
genetic background by serial backcross (see Materials and
Methods). The C57BL/6J background elicits the most
severe phenotype for the Pitpavb homozygote mice and is
Fig. 3. PitpaT59D is not a biologically functional protein. A: Lifespans for PITPa1/1 (open circles), Pitpa0/0
(closed circles), and Pitpa0/0,Tg(PitpaT59D) (open squares) mice are plotted. The data were obtained from
a dedicated pool of 176 mice with a genotypic distribution of 118 PITPa1/1, 26 Pitpa0/0, and 32 Pitpa0/0,
Tg(PitpaT59D). B: Images of PITPa1/1, Pitpa0/0, and Pitpa0/0,Tg(PitpaT59D) mice taken at the indicated ages. C:
Tg(PitpaT59D) protein is expressed at physiological levels. Immunoblot analysis of PITPa immunoreactive
species from whole brain (WBr), duodenum (Dnm), and liver, collected from P6 littermates of the indicated
genotypes, using a PITPa-specific C-terminal polyclonal antibody (top panels). The bottom panels depict
the corresponding blots that were stripped and reprobed with a b-actin-specific antibody for purposes
of normalization.
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minimized for the Pitpavb genetic modifiers detected in
other murine strain backgrounds (22). Comparisons of
the morbidity of Pitpa0/0 offspring as a function of genetic
background (C57BL/6J vs. 129SVJ) demonstrated that the
lifespans of nullizygotes were very similar in both genetic
background contexts (50% mortality at 4.2 6 1.2 vs. 4.8 6
0.7 days, respectively).
Standard mating schemes were used to generate C57BL/
6J-derived mice harboring Pitpa1/1, Pitpa1/0, Pitpavb/vb,
Pitpavb/0, and Pitpa0/0 allelic combinations. Relative levels
of endogenous PITPa in whole brain cytosol extracts
were prepared from mice of each genotype and compared
by immunoblotting and quantitative ELISA (Fig. 4A, B).
Again, in both experiments, antibodies specific for PITPa
were used to avoid confounding issues presented by the
highly similar PITPb isoform in these mice. In that re-
gard, PITPa1/1, PITPa1/vb, PITPa1/0, Pitpavb/vb, Pitpavb/0,
and Pitpa0/0 mice express ?100, 94, 61, 18, 13, and ,3%
of wild-type PITPa levels, respectively (Fig. 4B). These data
indicate that the titration range for PITPa was a satisfac-
torily broad one. For purposes of these studies, we focus
on PITPa1/1 and Pitpa0/0 strains as positive and null con-
trols, respectively, and Pitpavb/vb and Pitpavb/0 mice as experi-
mental variables.
Phenotypes of mice with graded reductions in
PITPa expression
Analyses of the allelic series emphasized the close
correlation between the primary phenotypes of PITPa-
deficient animals and levels of PITPa expression. From
the perspective of viability, Pitpa0/0 offspring exhibited a
steady mortality rate in the P0 to P11 window. Pitpavb/0
animals survived until P19 and then expired precipitously
over the next 3 days (Fig. 5A). Similarly, and in agree-
ment with previous reports (22, 31), Pitpavb/vb juveniles
persisted until P28 and then expired during the next
5 days. No deaths were scored for PITPa1/1 animals
during this period. Indeed, both PITPa1/vb and PITPa1/0
heterozygotes were phenotypically normal in every obvi-
ous way throughout their normal lifetime of ?24 months
(data not shown). The intermediate lifespan of Pitpavb/0
offspring, relative to Pitpa0/0 and Pitpavb/vb counterparts,
extended to other phenotypes. For example, Pitpavb/vb
juveniles were afflicted with a whole body tremor whose
onset was observed at P18. This onset advanced to P12
for Pitpavb/0 mice. Body mass analyses revealed a similar
pattern. Whereas a clear distinction in mass was already
apparent between PITPa1/1 and Pitpa0/0 littermates by
P5 (3.3 6 0.4 vs. 1.9 6 0.5 g; P , 0.003) (Fig. 5B), a
significant difference between the average body mass of
PITPa1/1 and Pitpavb/0 animals was not scored until P11
(Fig. 5B, C). This difference in mass coincided with onset
of the whole body tremor in the Pitpavb/0 animals, and it
exaggerated rapidly. By P15, Pitpavb/0 juveniles embarked on
a swift wasting process that persisted until death (Fig. 5B).
Quantitative relationship between PITPa activity and
steatosis of intestine and liver
A hallmark pathology of Pitpa0/0 neonates is a micro-
vesicular steatosis of duodenal enterocytes and liver. The
intestinal steatosis reflects the accumulation of dietary
fat in enterocytes as a result of defective transport of
that material from enterocytes into the circulation. These
steatotic phenotypes are proposed to reflect defects in
chylomicron biogenesis in enterocytes and lipid process-
ing in the liver, respectively (21). Steatosis is amenable
to histological examination by osmium staining of thin
tissue sections, and intestinal steatosis is also diagnosed
by analytical measurements of postprandial plasma TGs
and brain a-tocopherol. Although osmium staining of
duodenal and liver tissue sections revealed the expected
steatosis in Pitpa0/0 offspring, clear reductions in entero-
cytic and hepatic steatosis were observed in Pitpavb/0 sib-
lings. No overt steatotic pathologies were apparent in
Pitpavb/vb animals relative to wild-type sibling controls
(Fig. 6A, B).
The histological data were consistent with measure-
ments of postprandial plasma TGs and brain a-tocopherol.
Regarding plasma TG content, Pitpa0/0 neonates exhib-
ited ?4-fold reductions in circulating plasma TG relative
TABLE 1. PitpaT59D is nonfunctional in the mouse
Steatosis Mass
Genotype Age Serum Glucose Plasma TGs Intestine Liver
mM mg/dl g
PITPa1/1 P3 4.2 6 1.1 105.5 6 12.2
P5 8.1 6 1.5 128.7 6 7.4 222 222 3.5 6 0.4
P6 8.5 6 1.3 133.1 6 9.2
Pitpa0/0 P3 2.3 6 0.7 62.5 6 7.5
P5 2.1 6 0.5 56.3 6 8.8 111 111 2.6 6 0.4
P6 2.1 6 0.8 57.9 6 5.4
Pitpa0/0;Tg(PitpaT59D) P3 1.9 6 0.6 65.4 6 8.4
P5 2.4 6 0.9 55.7 6 5.6 111 111 2.4 6 0.3
P6 2.0 6 1.1 54.5 6 6.4
PITP, phosphatidylinositol transfer protein; TG, triglyceride, 111, severe steatosis. Values represent the
averages of values measured for three mice for each age and genotype. Serum glucose values were measured in
duplicate for each mouse to give an average value, which was then used to generate the average values reported
for each group. Single plasma TG measurements were taken for each mouse, and these values were then averaged
to yield the data shown. Serum glucose and plasma TG measurements were performed using the same blood
samples collected from each mouse. Steatosis of intestine and liver was monitored by osmium staining of organ
sections collected from mice of the indicated age and genotype.
Dissection of PITPa function in mice 1863
to PITPa1/1 siblings, whereas Pitpavb/0 mice showed only
an ?2-fold reduction in the same parameter. Pitpavb/vb off-
spring presented normal circulating plasma TG (Fig. 6C).
Similarly, the brain a-tocopherol deficit in Pitpa
0/0
off-
spring (0.69 6 0.31 vs. 2.71 6 0.45 ng/mg for PITPa1/1
siblings) was corrected in Pitpavb/0 and Pitpavb/vb brain
(2.60 6 0.32 and 2.51 6 0.56 ng/mg, respectively; Fig. 6D).
These data indicate that the intestinal and liver steatosis
pathologies manifest themselves only in the face of large
(>90%) reductions in PITPa expression.
Reconstitution of PITPa in small intestine of
Pitpa0/0 mice
The involvement of PITPa in chylomicron trafficking
from nullizygous enterocytes is puzzling, as the affected
organelle [endoplasmic reticulum (ER)] is the major intra-
cellular site of lipid synthesis. Moreover, it remains un-
known whether this pathology reflects a tissue-autonomous
defect and what CRD contributes to the complex disease
phenotypes of Pitpa0/0 neonates. To this end, a transgene
was engineered in which duodenum-specific expression
of PITPa cDNA is driven by the intestinal fatty acid bind-
ing protein enhancer [Tg(PIFABP::PITPa)] (Fig. 7A) (see
Materials and Methods). Immunoblotting experiments of
brain and intestine culled from PITPa1/1, Pitpa0/0, and
Pitpa0/0;Tg(PIFABP::PITPa) offspring confirmed that the
transgene supports a satisfactory tissue-specific expression
of physiologically relevant levels of PITPa (Fig. 7A).
Osmium staining demonstrated that Pitpa0/0;Tg(PIFABP::
PITPa) offspring were relieved of the intestinal steatosis
observed for their Pitpa0/0 siblings (Fig. 7B). The rescue-
of-steatosis phenotype exhibited tissue specificity, as liver
steatosis was not alleviated by Tg(PIFABP::PITPa) (Fig. 7C).
In fact, this liver pathology was, if anything, exacerbated.
Thin-section electron microscopy confirmed this effect
and indicated that the accumulated lipid in Pitpa0/0;
Tg(PIFABP::PITPa) liver is divided between what appears to
be a pool that resides in the ER lumen and a pool that
partitions into cytoplasmic lipid droplets (data not shown).
Rescue of intestinal steatosis, as scored by histological stain-
ing methods, was accompanied by improved transport of
chylomicron into the circulation. Pitpa0/0;Tg(PIFABP::PITPa)
animals exhibited 59.1 6 10.6% of the serum chylomicron
load of their age-matched PITPa1/1 controls. Relative to
Pitpa0/0 animals, whose circulating chylomicron load was just
24.7 6 8.8% of wild-type levels (Fig. 8A), this represented a
marked improvement.
Plasma TG and brain a-tocopherol enter the circula-
tion via the chylomicron pathway, and measurements of
these components were congruent with the chylomicron
data. Pitpa0/0;Tg(PIFABP::PITPa) neonates exhibited 59.2 6
5.9 mg/dl relative to 39.2 6 6.1 and 138.1 6 7.9 mg/dl
plasma TG for Pitpa0/0 and PITPa1/1 siblings, respectively
(Fig. 8B). Substantial rescue of brain a-tocopherol deficit
was similarly registered in Pitpa0/0;Tg(PIFABP::PITPa) off-
spring (3.04 6 0.72 vs. 1.19 6 0.22 and 3.99 6 0.68 ng/mg
brain tissue for Pitpa0/0 and PITPa1/1 littermates, re-
spectively; Fig. 8C). Thus, intestinal steatosis is a tissue-
autonomous pathology in Pitpa0/0 mice.
Lifespan and body mass measurements indicated that
duodenal PITPa expression levied modest improvement
in these parameters relative to Pitpa0/0 siblings. Although
?75% of the Pitpa0/0 offspring expired within the first
3 days after birth, some 80% of their Pitpa0/0;Tg(PIFABP::
PITPa) siblings survived past this benchmark (Fig. 9A). A
75% mortality standard was not reached for the Pitpa0/0;
Tg(PIFABP::PITPa) neonates until ?8 days after birth. Again,
although modest, this represents an effective doubling
of the Pitpa0/0 lifespan. Body mass measurements also
showed measurable increases in weight gain differential for
Pitpa0/0;Tg(PIFABP::PITPa) and Pitpa
0/0 neonates (Fig. 9B).
For instance, at P7, the respective mass differential was
3.1 6 0.3 versus 2.3 6 0.5 g (P 5 0.026).
PITPa expression and glucose homeostasis
Pitpa0/0 neonates are hypoglycemic. This condition is
suggested to contribute to the neurodegenerative pathol-
ogies and morbidity of mutant animals. Hypoglycemia
Fig. 4. Quantification of PITPa protein levels in a series of mice
harboring various PITPa mutant allele combinations. A: Immuno-
blot analyses of PITPa immunoreactive species from whole brain
lysates collected from P8 mice of the indicated genotypes. The top
panel presents immunoblot profiles obtained by probing the
indicated lysate preparations with a PITPa-specific antibody. The
bottom panel represents the same blot stripped and reprobed with
a b-actin-specific antibody as a normalization control. B: ELISA
analyses of PITPa protein levels from the same whole brain lysate
preparations described for A. Results are expressed as PITPa levels
relative to PITPa1/1 controls (set at 100%) after correction for
relative b-actin ELISA values. The values represent averages (plus
SD) from triplicate measurements for each of three independent
brain samples collected from three mice of each genotype.
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coincides with pancreatic islet defects, reduced prog-
lucagon expression, and inefficient glycogenolysis (21).
Consistent with previous findings, serum glucose was re-
duced by ?4-fold for Pitpa0/0 neonates compared with
wild-type littermate controls (2.0 6 0.1 vs. 8.3 6 0.2 mM;
Fig. 10A). By contrast, Pitpavb/0 neonates exhibited serum
glucose levels that were 2.8-fold higher than those of
Pitp0/0 mice (Fig. 10A). This increase was accompanied by
the restoration of efficient glycogenolysis in Pitpavb/0 ani-
mals (data not shown). Although an improvement, those
levels were still ?2-fold lower than those of PITPa1/1
siblings. PITPavb/vb animals exhibited no significant serum
glucose deficits relative to wild-type siblings (8.2 6 0.9 vs.
8.3 6 0.2 mM, respectively; Fig. 10A). Thus, as was found
for the microvesicular steatosis of duodenum and liver,
hypoglycemias associated with PITPa defects require
manifest reductions in PITPa activity (>90%).
Specific reconstitution of PITPa expression in the duo-
denum of Pitpa0/0 animals [Pitpa0/0;Tg(PIFABP::PITPa)] also
led to an increase in serum glucose, but this too was in-
complete. Circulating glucose values approached, but did
not meet, those measured for Pitpavb/0 mice (3.5 6 0.1 vs.
5.6 6 0.8 mM; Fig. 10A). Analyses of serum glucose as a
function of age were also informative. All neonates, re-
Fig. 5. Phenotyping of mice with graded levels of PITPa protein. A: Lifespan plots for PITPa1/1 (open
circles), Pitpavb/vb (closed squares), Pitpavb/0 (open squares), and Pitpa0/0 (closed circles) are shown. B: Aver-
age body masses of PITPa1/1 (open circles), Pitpavb/vb (closed squares), Pitpavb/0 (open squares), and Pitpa0/0
(closed circles) neonates are plotted in the P5 through P21 age window. Values represent averages over
lifespan for progeny derived from four independent litters for each genotype. No Pitpa0/0 neonates sur-
vived past P9 in these dedicated pools of animals. C: Images of P9, P14, and P19 PITPa1/1 and Pitpavb/0 mice
(left and right animals, respectively, in each panel).
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gardless of genotype, exhibited low blood glucose for the
first few days after birth. Although PITPa1/1 and Pitpavb/vb
animals rapidly overcame this condition, Pitpa0/0 progeny
did not (Fig. 10B). Pitpavb/0 and Pitpa0/0;Tg(PIFABP::PITPa)
neonates exhibited intermediate increases in serum
glucose with age but failed to meet the levels measured
for PITPa1/1 and Pitpavb/vb animals.
PITPa expression and cerebellar neurodegeneration
A hallmark phenotype of Pitpa0/0 mice is a robust hind-
brain and cerebellar inflammatory disease characterized
by reactive gliosis in these tissues (21). This pathology is
scored by staining for GFAP, a marker for activated astro-
cytes (Fig. 11A). It is suggested that the Pitpa0/0 cerebellum
is particularly sensitive to damage wrought by a systemic
energy crisis, such as that precipitated by the CRD and
hypoglycemia of Pitpa0/0 neonates (21). Consistent with this
proposal, cerebellar inflammatory disease was substantially
alleviated in both Pitpavb/vb and Pitpa0/0;Tg(PIFABP::PITPa)
neonates, as indicated by dramatic reductions in GFAP-
positive cells in tissue derived from those mice. By con-
trast, hindbrain inflammation was not alleviated in either
Pitpa0/0;Tg(PIFABP::PITPa) or Pitpa
vb/0 neonates (Fig. 11B).
The persistent hindbrain inflammation presumably
reflects some intrinsic fragility/deficit in Pitpa0/0 hind-
brain neurons.
PITPa nullizygosity and efficacy of synaptic transmission
Phosphoinositide signaling plays integral roles in regu-
lating neuronal membrane trafficking (32, 33). This raised
the possibility that PITPa regulates the synaptic cycle and
that the neurodegenerative disorder of Pitpa0/0 mice may
reflect central deficits in synaptic vesicle release and neuro-
transmission. To address this issue, basic properties of syn-
aptic transmission in the CA1 region of the hippocampus
were examined. The experimental model was justified by
two criteria. First, synaptic transmission in the hippocam-
pus is experimentally well characterized. Second, PITPa
is highly expressed in hippocampus, as indicated by LacZ
“knock-in” studies using a Pitpa::neo/puro/LacZ splice-trap
allele (20).b-Galactosidase staining of P10 PITPa1/ Pitpa::neo/
puro/LacZ brain sections revealed robust PITPa expression
in the hippocampus (Fig. 12A).
To compare basal synaptic strengths, age-matched
PITPa1/1 and Pitpa0/0 mice were used to facilitate hippo-
campal recordings. In these experiments, input-output
curves were generated by varying the stimulation intensity
of the Schaffer collateral inputs and recording the slope of
the fEPSP. The data indicate that basal synaptic strengths
were similar between PITPa1/1 and Pitpa0/0 mice (Fig. 12B;
P 5 0.949). To ensure that the relationship between pre-
synaptic neurotransmitter release and the postsynaptic re-
sponse was unchanged, the amplitudes of the fiber volley
(a gauge for presynaptic release) were compared with the
fEPSP slope (a gauge for synaptic response magnitude).
There were no significant differences between PITPa1/1
and Pitpa0/0 mice (Fig. 12C; P 5 0.26), suggesting that the
relationship between presynaptic release and the postsyn-
aptic response was preserved in Pitpa0/0 animals. To test
whether the disruption of normal PITPa activity might alter
the probability of presynaptic release and/or the degree
of synaptic vesicle mobilization, paired-pulse facilitations
across a range of interstimulus intervals were examined.
Facilitation did not differ between PITPa1/1 and Pitpa0/0
mice, as evaluated from fEPSP slopes (Fig. 12D; P 5 0.35)
or amplitudes (Fig. 12E; P 5 0.81). These data indicate
that mutant CA1 synapses exhibit normal probabilities of
neurotransmitter release and normal magnitudes of basal
synaptic transmission.
Presynaptic terminals of stratum radiatum neurons were
also examined by quantitative morphometry. Defects in
the synaptic vesicle cycle should result in abnormal syn-
aptic vesicle densities in such presynaptic terminals.
PITPa1/1 and Pitpa0/0 littermate mice (four each) were
perfused with mixed aldehydes, and brains were collected
and embedded. Embedded brains were sectioned through
the hippocampus, further processed, and flat-embedded
in plastic (34). Blindly coded sample blocks were pre-
pared from the CA1 region of hippocampus, and mor-
phometric analyses focused on synapses in the stratum
radiatum. A total of 117 images of randomly selected ter-
Fig. 6. Chylomicron metabolism in mice with varying levels of
PITPa activity. A, B: Osmium staining of intestinal (A) and liver
(B) tissue. Panels depict paraffin-embedded, osmium-stained intes-
tinal and liver sections of P8 mice from the indicated genotypes.
Steatosis is scored by intensity of osmium staining (black). C: Post-
prandial plasma triglyceride (TG) levels as a function of age.
Plasma was harvested from three age-matched PITPa1/1 (open cir-
cles), Pitpa0/0 (closed circles), Pitpavb/0 (open squares), and Pitpavb/vb
(closed squares) animals and measured in triplicate for each mouse
at each time point. D: Brain a-tocopherol measurements. Whole
brains from age-matched (P6) PITPa1/1 and Pitpa0/0 mice, as well as
from age-matched (P16) PITPa1/1, Pitpavb/0, and Pitpavb/vb animals,
were harvested and corresponding extracts were assayed for a-
tocopherol. Measurement averages with SD are shown. Genotypes
are listed at bottom.
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minals with recognizable synapses were collected, 59 from
PITPa1/1 animals and 58 from Pitpa0/0 mice. For each ter-
minal, vesicles were counted within a 0.2 mm square area:
0.1 mm lateral to each side from the center of the oppos-
ing postsynaptic density and 0.2 mm back into the ter-
minal. The number of vesicles per examined area ranged
from 0 to 19. The PITPa1/1 and Pitpa0/0 mice averaged
6.4 and 7.7 vesicles per synapse, respectively. Although
there were the expected variations in the numbers of vesi-
cles per synapse, no obvious correlation between vesicle
number and PITPa status was discerned. Thus, the col-
lective electrophysiological and morphometric data in-
dicate that the synaptic vesicle cycle of Pitpa0/0 mice is
unperturbed, and that neurodegeneration is unlikely to
be a consequence of deficits in synaptic transmission.
DISCUSSION
Here, we report a detailed analysis of PITPa function
in mice. These studies take advantage of transgenic ap-
proaches to achieve three purposes. First, the contribution
of PtdIns binding to PITPa function in vivo was evaluated.
Second, a series of isogenic mouse strains with graded
reductions in PITPa activity was analyzed to examine the
relationships between the complex pathologies apparent
in Pitpa0/0 neonates. Third, the consequences of recon-
stituting PITPa expression solely in the small intestine of
Pitpa0/0 animals were assessed. The conclusions derived
from these analyses are as follows: i) PtdIns binding activity
is essential for PITPa function in the mouse; ii) the
lifespan of neonatal and juvenile mice is highly sensitive
to levels of PITPa; iii) large reductions in PITPa expres-
sion are required for the elaboration of intestinal and
liver steatotic phenotypes and hypoglycemia; iv) intestinal
steatosis is a tissue-autonomous pathology that is rescued
by tissue-specific expression of PITPa; v) hindbrain neuro-
degenerative processes can be largely uncoupled from
intestinal/liver steatosis and hypoglycemia, whereas cere-
bellar inflammatory disease cannot; and vi) elimination of
PITPa activity has no apparent consequence for synaptic
efficacy, even in neurons that normally exhibit high levels
of PITPa expression. Together, these data provide the first
in vivo demonstration of a meaningful biological role for
Fig. 7. Intestinal expression of PITPa in Pitpa0/0 mice. A: The upper panels describe the vectors used to
generate Tg(PIFABP::PITPa
1). Plasmid pNSE-EX4 was used as an expression vector backbone, and PITPa
expression was engineered under the control of the intestinal fatty acid binding protein promoter (PIFABP)
(see Materials and Methods). The lower panels show the results of immunoblot analyses using lysates
prepared from whole brain (WBr) or duodenum (Dnm) preparations collected from mice of the indicated
genotypes. Immunoblot profiles at top monitor PITPa, whereas the immunoblot profiles at bottom re-
cord the corresponding b-actin profiles for purposes of normalization. B: Age-matched (P6 littermates)
duodenal sections stained with osmium. Genotypes are indicated. C: Liver sections from P6 littermates
stained with osmium. Genotypes are indicated.
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PtdIns binding by PITPa. The data also bolster the idea that
PITPa plays a role in the biogenesis and transport of lipid/
lipoprotein cargo from intracellular organelles.
PtdIns binding and PITPa function
Current models suggest that PITPa is devoted primarily
to phosphoinositide synthesis, particularly PtdIns-4,5-P2
synthesis (35–38). Such a role could involve a direct cou-
pling between PITPa and PtdIns 4-OH kinases, in which
PITPa presents PtdIns to the enzyme and thereby poten-
tiates its catalytic activity. A more indirect PtdIns delivery
mechanism, in which PITPa supplies PtdIns to sites of
active signaling from other intracellular membranes (e.g.,
by PtdIns transfer), is also plausible. Alternatively, PITPa
could stimulate PtdIns-4,5-P2 synthesis by potentiating phos-
pholipase D-mediated hydrolysis of PtdCho [and subse-
quently stimulating PtdIns-4-phosphate 5-OH kinase activity
via the production of the phosphatidic acid hydrolytic prod-
uct (39)]. The former two models predict a critical role for
PtdIns binding by PITPa, whereas the latter model em-
phasizes PtdCho binding. The finding that physiological
levels of expression of PitpaT59D, as the sole source of
PITPa in the mouse, recapitulate phenotypes of Pitpa0/0
mice, identifies PtdIns binding as an essential functional
property of PITPa. This demonstration is most consistent
with either PtdIns presentation, or PtdIns transfer, mecha-
nisms for PITPa function in vivo. To distinguish between the
presentation and transfer mechanisms, it is necessary to
assess the in vivo functionality of mutant PITPa forms with
defects in PtdCho binding. Unfortunately, available struc-
tural information does not reveal how to generate such
PtdCho binding-defective forms of PITPa.
Phenotypic consequences of graded reductions in
PITPa expression
Pitpa0/0 mice experience a complex disease course of in-
testinal and hepatic steatosis, hypoglycemia, and inefficient
glycogenolysis (stemming from pancreatic insufficiency)
and a fulminating spinocerebellar neurodegenerative dis-
ease. The neurodegeneration is marked by reactive gliosis
of the cerebellum and hindbrain and aponecrotic pathol-
ogies in the spinal cord (21). The relationships between
these various pathologies is not obvious, however. Analyses
of isogenic mouse lines with graded reductions in PITPa
Fig. 8. Chemical analyses of Pitpa0/0 mice expressing PITPa in the duodenum. A: Postprandial serum
chylomicron levels. A Titan lipoprotein agarose gel is shown at left. Genotypes of P5 littermates are in-
dicated, and bands are identified as follows: Chyl, chylomicron; LDL, low density lipoprotein; HDL, high
density lipoprotein. The right panel represents quantification (by densitometry) of chylomicron bands from
a total of five animals of each indicated genotype. Tg indicates the Tg(PIFABP::PITPa
1) allele. PITPa1/1 values
were uniformly set at 100%, and Pitpa0/0 and Pitpa0/0,Tg(PIFABP::PITPa
1) values were related to that bench-
mark. B: Postprandial plasma TG levels as a function of age. Plasma TGs from three age-matched litter-
mates (as indicated) were measured. Avg. indicates the average of all sample measurements for that
particular genotype [PITPa1/1, open circles; Pitpa0/0, closed circles; Pitpa0/0,Tg(PIFABP::PITPa
1), open tri-
angles]. C: Whole brain a-tocopherol measurements. Four age-matched littermates of each indicated
genotype were analyzed. Averaged values with SD are reported. Tg indicates Tg(PIFABP::PITPa
1).
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expression clarify some of these relationships. First, it is
clear that the hindbrain inflammatory and spinal cord
neurodegenerative diseases are intrinsic pathologies of
PITPa-insufficient mice, as these can be uncoupled from
intestinal/liver steatosis and hypoglycemia. This is most
apparent in the case of Pitpavb/vb mice, which express
?20% of wild-type levels of PITPa activity. Pitpavb/vb ani-
mals suffer from both hindbrain and spinal cord neuro-
degeneration (22, 31) but fail to exhibit any symptoms of
overt intestinal/liver steatosis or hypoglycemia. By con-
trast, both intestinal/liver steatosis and hypoglycemia are
apparent only in mice in which PITPa activity is reduced
by >90% (i.e., Pitpa0/0 and Pitpavb/0 lines). Moreover, the
severities of the respective pathologies are closely corre-
lated. Pitpavb/0 mice exhibit a less severe intestinal/liver
steatosis than Pitpa0/0 siblings. Pitpavb/0 mice also show a
significantly reduced hypoglycemia. These data are con-
sistent with the view that the hypoglycemia of PITPa-
insufficient mice is secondary to intestinal/hepatic lipid
transport defects.
Fig. 9. Characterization of Pitpa0/0,Tg(PIFABP::PITPa
1) mice. A:
Lifespan profiles for PITPa1/1 (open circles), Pitpa0/0 (closed cir-
cles), and Pitpa0/0,Tg(PIFABP::PITPa
1) (open triangles) mice are com-
pared. The data were obtained from a dedicated pool of 148 mice
with a genotypic distribution of 100 PITPa1/1, 21 Pitpa0/0, and
27 Pitpa0/0,Tg(PIFABP::PITPa
1). B: Visual characterization and body
mass measurements of Pitpa0/0,Tg(PIFABP::PITPa
1) mice. The upper
panel shows images of P4 (left) and P7 (right) mice. For each
panel, genotypes of mice (from left to right) are PITPa1/1, Pitpa0/0,
and Pitpa0/0,Tg(PIFABP::PITPa
1). The lower panel charts body
mass as a function of age for PITPa1/1 (open circles), Pitpa0/0
(closed circles), and Pitpa0/0,Tg(PIFABP::PITPa
1) (open triangles).
Data were obtained from the same dedicated pool of 148 mice used
for A. Body mass values were averaged for each genotypic group. SD
values are shown.
Fig. 10. PITPa levels and glucose homeostasis. A: Average serum
glucose values measured from age-matched (P4–P6) PITPa1/1,
Pitpa0/0, Pitpa0/0,Tg(PIFABP::PITPa
1), Pitpavb/0, and Pitpavb/vb mice.
The genotypes are indicated at bottom. B: Serum glucose levels
as a function of age. PITPa1/1 (open circles), Pitpa0/0 (closed
circles), Pitpa0/0,Tg(PIFABP::PITPa
1) (open triangles), Pitpavb/0 (open
squares), and Pitpavb/vb (closed squares) serum glucose were deter-
mined at the indicated ages. No Pitpa0/0 or Pitpa0/0,Tg(PIFABP::PITPa
1)
measurements were available beyond P8, as no animals survived
past this threshold. Data were obtained from triplicate determina-
tions from each of three mice of each genotype at each time
point. The serum glucose values were quite constant for Pitpa0/0
and Pitpa0/0,Tg(PIFABP::PITPa
1) mice in the P3–P8 time window
(2.3 6 0.5 vs. 3.8 6 0.6 mM, respectively), and these differences
were significant (P , 0.0002).
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Reconstitution of PITPa expression in small intestine
The intestinal steatosis of Pitpa0/0 mice is an intriguing
phenotype. Its characteristics are consistent with a defect
in the biogenesis/transport of chylomicrons from the
enterocyte ER (21). Indeed, the steatotic condition (and
its consequences) resemble those of human CRD (40, 41).
One underlying mechanism for human CRD stems from
defects in a specific isoform of the Sar1-GTPase (42). This
raises the attractive possibility that specific components
of the COPII ER vesicle-budding machinery are dedicated
to the biogenesis of vesicles containing atypical cargo, such
as chylomicrons.
A role for PITPa in chylomicron biogenesis/trafficking
is unanticipated, as it is not obvious why such a protein
would be required for ER transport processes, given that
the ER is the major site of lipid synthesis in cells. More-
over, the ER is not an acknowledged site of phosphoinosi-
tide signaling. Yet, the available data indicate a connection
between PITPa function and chylomicron metabolism.
Specific defects in PITPa PtdIns binding are sufficient to
elicit CRD-like symptoms in PitpaT59D-expressing mice.
Moreover, reexpression of PITPa in the small intestine of
Pitpa0/0 mice alleviates the steatotic phenotype of this
organ and partially rescues the biochemical defects asso-
ciated with CRD. Pitpa0/0;Tg(PIFABP::PITPa) neonates
also exhibit increased plasma TG levels, increases in the
quantities of circulating chylomicrons, and increased
brain a-tocopherol levels (a vitamin whose transport into
the circulation is dependent on the chylomicron path-
way) relative to Pitpa0/0 controls. The rescue experiment
additionally identifies the intestinal steatosis as a tissue-
autonomous pathology in Pitpa0/0 mice.
Although reconstitution of PITPa expression in the
small intestine does have discernible effects, it none-
theless supports only a modest rescue of plasma TG defi-
cits and hypoglycemia and only modest increases in the
lifespan of transgenic Pitpa0/0 animals. Exacerbated liver
steatosis is observed in these mice, however. As chylo-
micron remnants are taken up by the liver, remodeled,
and reexported as VLDL particles, we suggest that de-
fects in lipoprotein processing/biogenesis in Pitpa0/0 liver
significantly neutralize the benefits realized by rescue of
the intestinal steatosis. These data suggest a role for PITPa
in the hepatic lipoprotein biogenesis/transport pathway,
a reasonable possibility given that the pathways for lipo-
protein biogenesis and transport are similar in the small
intestine and the liver (43–45). We predict that reconsti-
tution of PITPa expression in both the small intestine
and the liver of a Pitpa0/0 mouse will yield what is a symp-
tomatically Pitpavb/vb mouse.
Differential causes of neurodegenerative disease
It was previously proposed that neonatal Pitpa0/0 cere-
bellum is especially susceptible to injury because its pro-
gram of robust cell proliferation is incompatible with the
hypoglycemic environment presented by the nullizygous
mouse (21). The results reported here are consistent with
this idea. Both Pitpavb/0 and Pitpa0/0;Tg(PIFABP::PITPa)
neonates are substantially free of the dramatic reactive
gliosis that characterizes their Pitpa0/0 siblings. This is a
telling result in the context of the Pitpa0/0;Tg(PIFABP::PITPa)
mouse, as the cerebellum fails to express PITPa yet is spared
the normal course of inflammatory disease by PITPa ex-
pression in the small intestine. Consistent with these data,
cerebellar granule cells cultured from PITPa1/1 and Pitpa0/0
neonates show no obvious differences in vigor when cultured
in vitro (i.e., under culture conditions in which defects as-
sociated with systemic lipid transport and hypoglycemia are
irrelevant; data not shown).
As hindbrain and spinal cord defects are not alleviated
by PITPa expression in the duodenum, these pathologies
reflect intrinsic neuronal defects of PITPa-insufficient
mice. These pathologies do not stem from deficiencies
in the synaptic vesicle cycle, given that synaptic function
is not adversely affected by genetic ablation of PITPa ac-
tivity in hippocampal neurons. Whether these intrinsic
defects reflect improper neuronal development and de-
fects in proper path finding (46) or some other signaling
defect(s) remains to be determined.
This work was supported by National Institutes of Health Grant
NS-37723 (to V.A.B.). B.D.P. was supported by the Whitehall
Foundation. The authors thank G. Grossman, H. Mekheel, and
Fig. 11. Cerebellar neurodegeneration and PITPa expression.
Sagittal sections of cerebellum (A) or hindbrain (B) were infil-
trated with paraffin and stained for glial fibrillary acidic protein.
Genotypes are indicated; Tg indicates the Tg(PIFABP::PITPa1) allele.
Tissue sections were from P8 animals except for Pitpavb/0 mice, for
which P14 animals were used. These ages were chosen on the basis
that neurodegenerative disease had progressed to the obvious
whole body tremor stage.
1870 Journal of Lipid Research Volume 48, 2007
J. de Marchena for valuable technical assistance and Margaret
Ryan for help with Fig. 1. The authors also acknowledge the
services of the University of North Carolina Lineberger Com-
prehensive Cancer Center Genome Analysis and Nucleic Acids
Core Facilities, and Tammy Elliott and Melinda Beck from
the University of North Carolina Clinical Nutrition Research
Center (supported by National Institutes of Health Grant DK-
56350). Particular thanks are extended to Kris Phend and
Richard Weinberg (University of North Carolina) for quan-
titative morphometry data and to JrGang Cheng of the Uni-
versity of North Carolina Neuroscience Center Bacterial
Artificial Chromosome Engineering Core Facility for reagents
and helpful advice.
REFERENCES
1. Simons, K., and E. Ikonen. 1997. Functional rafts in cell mem-
branes. Nature. 387: 569–572.
2. Kurzchalia, T. V., and R. G. Parton. 1999. Membrane microdomains
and caveolae. Curr. Opin. Cell Biol. 11: 424–431.
3. Fujiwara, T., K. Ritchie, H. Murakoshi, K. Jacobson, and A. Kusumi.
2002. Phospholipids undergo hop diffusion in compartmentalized
cell membrane. J. Cell Biol. 157: 1071–1082.
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